Eli Lilly and Company (NYSE:LLY) Shares Sold by Hamilton Capital Partners LLC

Hamilton Capital Partners LLC reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 91.0% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 601 shares of the company's stock after selling 6,104 shares during the period. Eli Lilly and Company makes up 0.3% of Hamilton Capital Partners LLC's investment portfolio, making the stock its 17th largest holding. Hamilton Capital Partners LLC's holdings in Eli Lilly and Company were worth $496,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of LLY. Mascagni Wealth Management Inc. purchased a new position in Eli Lilly and Company during the 4th quarter worth $43,000. FPC Investment Advisory Inc. grew its position in Eli Lilly and Company by 358.3% during the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after purchasing an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. purchased a new position in Eli Lilly and Company during the 4th quarter worth $48,000. Highline Wealth Partners LLC grew its position in Eli Lilly and Company by 53.3% during the 1st quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock worth $57,000 after purchasing an additional 24 shares during the last quarter. Finally, Capital A Wealth Management LLC purchased a new position in Eli Lilly and Company during the 4th quarter worth $63,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $21.61 during midday trading on Friday, hitting $763.43. The company had a trading volume of 6,197,089 shares, compared to its average volume of 3,668,639. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The business has a 50-day simple moving average of $780.48 and a two-hundred day simple moving average of $800.93. The firm has a market capitalization of $723.53 billion, a price-to-earnings ratio of 62.12, a price-to-earnings-growth ratio of 1.11 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business's revenue was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.58 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date was Friday, May 16th. Eli Lilly and Company's payout ratio is currently 48.82%.

Analysts Set New Price Targets

Several brokerages have recently weighed in on LLY. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their target price for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 target price on the stock. Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday, June 7th. Finally, Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $1,011.79.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.